Houston Methodist Hospital is on everyone’s lips, after they successfully treated some seriously ill COVID-19 patients with a new drug.
A new drug known as RLF-100 or aviptadil has been used to treat COVID-19 patients and the Hospital has reported the quick recovery of these patients. The FDA has approved this drug to be used for emergency purposes. This drug can be used for patients who are too ill to go through the phase 2/3 trials of the FDA.
NeuroRX’s press release revealed that independent researchers reported that the use of aviptadil closed up the replication of the SARS coronavirus in human lung cells. The report claimed that a COVID-19 patient who was being treated stopped using a ventilator within four days of administering this drug. Similar results have been seen in over 15 patients.
According to the police, this drug seemed to have improved blood oxygen, cleared pneumonitis, and had resulted in a decrease in COVID-19 inflammation.
No other antiviral agent has demonstrated rapid recovery from viral infection and demonstrated laboratory inhibition of viral replication. We are conducting placebo-controlled trials to see whether the observations made in the case-control and open-label studies will be confirmed for less ill patients with COVID-19-related respiratory failure. Our independent Data Monitoring Committee will be conducting an interim analysis of these data later this month.Prof. Jonathan Javitt (The Chairman and CEO of NeuroRX)